This database contains 60 studies, archived under the term: "events"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Ginkgo biloba prevention trials: More than an ounce of prevention learned
Objective: To determine effectiveness of G biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). Design, Setting, and Participants: Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and […]
Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: Results from an international survey
Froelich, Lutz,
Andreasen, Niels,
Tsolaki, Magda,
Foucher, Arnaud,
Kavanagh, Shane,
Van Baelen, Bart,
Schwalen, Susanne
Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial
Cummings, J. L.,
Lyketsos, C. G.,
Peskind, E. R.,
Porsteinsson, A. P.,
Mintzer, J. E.,
Scharre, D. W.,
De La Gandara, J. E.,
Agronin, M.,
Davis, C. S.,
Nguyen, U.,
Shin, P.,
Tariot, P. N.,
Siffert, J.
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]
Memantine in moderately-severe-to-severe Alzheimer’s disease: A postmarketing surveillance study
Clerici, Francesca,
Vanacore, Nicola,
Elia, Antonietta,
Spila-Alegiani, Stefania,
Pomati, Simone,
Da Cas, Roberto,
Raschetti, Roberto,
Mariani, Claudio
Background: Postmarketing surveillance studies (PMS) are an important tool for evaluating a drug’s effectiveness and safety in clinical practice. To our knowledge, no PMS on memantine monotherapy for moderately-severe-to-severe Alzheimer’s disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria has been conducted to date. Objective: […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Treatment with Huperzine A improves cognition in vascular dementia patients
Xu, Zhi-Qiang,
Liang, Xiao-Min,
Juan, Wu,
Zhang, Yuan-Feng,
Zhu, Chun-Xia,
Jiang, Xiao-Jiang
Unlabelled: In the present study, we tested the efficacy and safety of Huperzine A in treatment of mild to moderate vascular dementia (VaD). This was a randomized, double-blinded, placebo-controlled study with 78 patients with mild to moderate VaD. The participants were randomized to receive either vitamin C (100-mg bid) as placebo (n = 39) or […]
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
Uenaka, Kazunori,
Nakano, Masako,
Willis, Brian A.,
Friedrich, Stuart,
Ferguson-Sells, Lisa,
Dean, Robert A.,
Ieiri, Ichiro,
Siemers, Eric R.
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.; Methods: Japanese and white patients with mild to moderate AD […]
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease
Sanchez-Ramos, Juan,
Cimino, Cynthia,
Avila, Ross,
Rowe, Amanda,
Chen, Ren,
Whelan, Glenn,
Lin, Xiaoyang,
Cao, Chuanhai,
Ashok, Raj
Human granulocyte colony-stimulating-factor (G-CSF) is widely used for treatment of neutropenia and to mobilize stem/progenitor cells for bone marrow transplantation. In studies of thousands of healthy donor subjects treated with G-CSF to mobilize stem/progenitor cells, the side-effect profile has been reported to be mild and reversible. In pre-clinical studies, G-CSF was reported to improve spatial […]